spacer
home > ebr > winter 2003 > the future of biomanufacturing
PUBLICATIONS
European Biopharmaceutical Review

The Future of Biomanufacturing

In my previous article, I reviewed the recent history of biopharmaceutical manufacturing, and the factors that have driven the industry to be the size and shape that it is today. In this article, I will be looking at the emerging trends and technologies, and considering the influence that they will have on biopharmaceutical manufacturing in the future.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Sharon Grimster, Director of Westerly Projects Ltd

Sharon Grimster started her career working on clinical trials at Guys Hospital Medical School in London. She then moved to Celltech, working in research for four years prior to taking up various management positions within contract manufacturing. Sharon subsequently managed preclinical and clinical development programmes for both new chemical entities and biological entities. Following the mergers with Chiroscience and Medeva, Sharon became Head of Biologics Manufacturing Development. She left Celltech in 2002 and is now a Director of Westerly Projects Ltd, a consultancy company offering development services to the biopharmaceutical industry globally.

spacer
Sharon Grimster
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

High Throughput Analytics Herald a Paradigm Shift in the Development of Biopharmaceuticals

Heilbronn/Dortmund August 2019: Biopharmaceuticals have revolutionized therapies of various diseases. In particular with regard to chronical and/or severe clinical conditions like multiple sclerosis, rheumatoid arthritis or cancer they are considered the future of treatment. Also economically biological drugs are on their way up: The global biopharmaceuticals market is anticipated to reach about 400 billion USD by 2025. Which strategic alignment will help best to fill a successful pipeline?
More info >>

White Papers

Migration safe pharmaceutical labels improve patient safety

UPM Raflatac

Labels play an invaluable role on pharmaceutical packages. Pharmaceutical companies should only use labels that meet low-leachability and extraction requirements. Labels that are not migration safe, e.g. create leachable chemical compounds, may fail testing and result in significant launch delays or costly recalls. This white paper presents how pharmaceutical companies can ensure that the final label constructions achieve their business, regulatory and patient safety goals.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement